Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin

Figures & data

Table 1 Patient Demographics (N = 122)

Patient Characteristics
	CD			CP		P
	N	%		n	%
Total	42			80
Age						0.1149
Mean	56			53
Range	31–72			33–74
Status						0.7661
1st recurrence	31	74		61	76
2nd recurrence	11	26		19	24
Initial FIGO Stage						0.0495
I-II	8	19		29	36
III-IV	34	81		51	64
Primary Histology						0.3376
Serous	34	80		54	68
Endometroid	2	5		13	16
Clear cell	4	10		9	11
Mucinous	2	5		3	4
Other	0	0		1	1
Platinum Free Interval						0.7668
Median	12.4			14
Range	6.2–79.6			6.2–76.1
6–12 months	19	45		30	38
>12 months	23	55		50	62
No. Of Chemotherapy Courses						0.426
3	5	12		4	5
4	1	2		3	4
5	1	2		5	6
≥6	35	84		68	85
Surgery For This Recurrence						0.3787
No surgery	21	50		31	39
Optimal cytoreductive surgery	19	45		41	51
Suboptimal cytoreductive surgery	2	5		8	10
Chemotherapy Response						0.1359
Complete response	18	43		51	64
Partial response	7	17		10	12
Stable disease	8	19		11	14
Progressive disease	9	21		8	10

Figure 1 Progression-free survival of CP and CD groups.

Figure 2 Progression-free survival in relation to platinum-free interval (PFI). (A) Patients with PFI 6–12 months. (B) Patients with PFI >12 months.

Figure 3 Progression-free survival based on relapse. (A) Patients with first recurrence. (B) Patients with second recurrence.

Table 2 Multivariate Analysis Of Predictive Factors On Progression-Free Survival After Second Relapse

Factors	Multivariate Cox Regression Model
	HR (95% CI)	95% CI	p-Value
Age
<50	1	0.09–1.00	0.05
≥50	0.3
Chemotherapy for First Relapse
CP	1	0.15–1.81	0.301
CD	0.36
PFI
6–12M	1	0.21–1.35	0.186
>12M	0.54
Chemotherapy for Second Relapse
CP	1	0.14–0.94	0.038
CD	0.51